Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations

Clinical Cancer Research

Volumn 19, Issue 13, 2013, Pages 3474-3484

  George, Joshy ^a,b   Alsop, Kathryn ^a,b   Etemadmoghadam, Dariush ^a,b   Hondow, Heather ^a   Mikeska, Thomas ^a,b   Dobrovic, Alexander ^a,b   DeFazio, Anna ^d,e   Smyth, Gordon K ^b,c   Levine, Douglas A ^f   Mitchell, Gillian ^a,b   Bowtell, David D ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GRADING; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FEMALE; GENE AMPLIFICATION; GENE DISRUPTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS; CARCINOMA; CHROMOSOME 19; CHROMOSOME 8; CHROMOSOME ABERRATION; EPISTASIS; GENE EXPRESSION REGULATION; GENETICS; GERMLINE MUTATION; METABOLISM; MUTATION; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; X CHROMOSOME;

CARCINOMA; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 19; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, X; DNA COPY NUMBER VARIATIONS; EPISTASIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MUTATION; NEOPLASM GRADING; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84879878171     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0066     Document Type: Article

References (50)

1. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34. (Pubitemid 37328884)
2. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
3. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011;17:2538-48.
4. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007;5:35-44. (Pubitemid 350218778)
5. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25.
6. Kobel M, Kalloger SE, Baker PM, Ewanowich CA, Arseneau J, Zherebitskiy V, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol 2010;34:984-93.
7. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
8. Alsop K, Fereday S, Meldrum C, Defazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol 2012;30:2654-63.
9. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011;121:353-7.
10. Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ, Edmondson RJ. Defective homologous recombination in human cancers. Cancer Treat Rev 2012;38:89-100.
11. Jazaeri A, Yee C, Sotiriou C, Brantley K, Boyd J, Liu E. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002;94:990-1000. (Pubitemid 34814728)
12. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28:3555-61.
13. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 2009;15:1417-27.
14. Rozen S, Skaletsky H. Primer3 on the WWW for general use and for biologist programmers. In:Misener S, Krawetz SA, editors. Bioinformatics methods and protocols. Vol. 132. Totowa, NJ: Humana Press Inc.; 2000. p. 365-86.
15. Berchuck A, Heron K-A, Carney M, Lancaster J, Fraser E, Vinson V, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998;4:2433-7. (Pubitemid 28477909)
16. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-406. (Pubitemid 35154144)
17. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000;60:5329-33.
18. Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P. Promoter hypermethylation of the PALB2 susceptability gene in inherited and sporadic breast and ovarian cancer. Cancer Res 2008;68:998-1002. (Pubitemid 351272217)
19. Wang Z, Li M, Lu S, Zhang Y, Wang H. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther 2006;5:256-60.
20. Mikeska T, Alsop K, Australian Ovarian Cancer Study Group, Mitchell G, Bowtell D, Dobrovic A. No evidence for PALB2 methylation in high-grade serous ovarian cancers. J Ovarian Res 2013;6:26.
21. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS ONE 2011;6:e18064.
22. Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res 2012;40:e133.
23. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, et al. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS ONE 2010;5:e11408.
24. Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, Almendro V, et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A 2010;107:9742-6.
25. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, et al. Ampli fication of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res 2007;13:5745-55. (Pubitemid 47583899)
26. McBride DJ, Etemadmoghadam D, Cooke SL, Alsop K, George J, Butler A, et al. Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J Pathol 2012;227:446-55.
27. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121-32. (Pubitemid 43202662)
28. Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011;22:1346-52.
29. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
30. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9. (Pubitemid 39331153)
31. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82. (Pubitemid 34161138)
32. Greenberg RA, Sobhian B, Pathania S, Cantor SB, Nakatani Y, Livingston DM. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 2006;20:34-46. (Pubitemid 43042666)
33. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012;12:68-78.
34. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30. (Pubitemid 36530000)
35. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012;307:382-90.
36. Lakhani SR. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res 1999;1:31-5. (Pubitemid 32223533)
37. Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, et al. Morphologic patterns associated withBRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 2012;25:625-36.
38. Fujiwara M, McGuire VA, Felberg A, Sieh W, Whittemore AS, Longacre TA. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identi fication of a BRCA1 ovarian cancer phenotype. Am J Surg Pathol 2012;36:1170-7.
39. Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) 2011;4:23-33.
40. Bekker-Jensen S, Lukas C, Kitagawa R, Melander F, Kastan MB, Bartek J, et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol 2006;173:195-206.
41. Press JZ, Wurz K, Norquist BM, Lee MK, Pennil C, Garcia R, et al. Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. Neoplasia 2010;12:993-1002.
42. Shamovsky I, Nudler E.New insights into the mechanism of heat shock response activation. Cell Mol Life Sci 2008;65:855-61.
43. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinoma with platinum resistance. Cancer Res 2008;68:2581-6. (Pubitemid 351556255)
44. Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 2011;102:663-9.
45. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486:405-9.
46. Grushko TA, Dignam JJ, Das S, Bloackwood AM, Perou CM, Ridderstrale KK, et al.MYCis amplified inBRCA1-associated breast cancers. Clin Cancer Res 2004;10:499-507. (Pubitemid 38173988)
47. Wang Q, Zhang H, Kajino K, Greene MI. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 1998;17:1939-48. (Pubitemid 28488462)
48. Jazaeri AA, Chandramouli GV, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, et al. BRCA1-mediated repression of select X chromosome genes. J Transl Med 2004;2:32.
49. Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers ofBRCA1. J Natl Cancer Inst 2008;100:1519-29.
50. Silver DP, Dimitrov SD, Feunteun J, Gelman R, Drapkin R, Lu SD, et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell 2007;128:991-1002. (Pubitemid 46341424) Defense Defense